---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-25-000040"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:42:08.051992+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum Q2 revenue $127.8M; raises FY 2025 guidance to $490-510M

## Summary
- Q2 global net product sales $127.8M, up 64% YoY from $77.9M.
- LIVMARLI sales $88.2M (+87% YoY); Bile Acid Medicines $39.6M (+30%).
- FY 2025 revenue guidance raised to $490-510M from prior range.
- Cash $321.7M; volixibat VISTAS topline expected Q2 2026.
- MRM-3379 Phase 2 in Fragile X expected Q4 2025 initiation.

## SEC filing metadata
- accession: 0001759425-25-000040
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/0001759425-25-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/mirm-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-25-000040
- JSON: https://secwatch.observer/filing/0001759425-25-000040.json
- Plain text: https://secwatch.observer/filing/0001759425-25-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.